25 XP   0   0   10

Kyongbo Pharmaceutical Co Ltd
Buy, Hold or Sell?

Let's analyse Kyongbo Pharmaceutical Co Ltd together

PenkeI guess you are interested in Kyongbo Pharmaceutical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kyongbo Pharmaceutical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kyongbo Pharmaceutical Co Ltd

I send you an email if I find something interesting about Kyongbo Pharmaceutical Co Ltd.

Quick analysis of Kyongbo Pharmaceutical Co Ltd (30 sec.)










What can you expect buying and holding a share of Kyongbo Pharmaceutical Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
₩0.07
When do you have the money?
1 year
How often do you get paid?
65.8%

What is your share worth?

Current worth
₩6,039.32
Expected worth in 1 year
₩6,067.65
How sure are you?
76.3%

+ What do you gain per year?

Total Gains per Share
₩128.11
Return On Investment
1.7%

For what price can you sell your share?

Current Price per Share
₩7,440.00
Expected price per share
₩7,440 - ₩7,440
How sure are you?
50%

1. Valuation of Kyongbo Pharmaceutical Co Ltd (5 min.)




Live pricePrice per Share (EOD)

₩7,440.00

Intrinsic Value Per Share

₩9,010.43 - ₩10,914.75

Total Value Per Share

₩15,049.75 - ₩16,954.07

2. Growth of Kyongbo Pharmaceutical Co Ltd (5 min.)




Is Kyongbo Pharmaceutical Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$101m$100.1m-$464.1k-0.5%

How much money is Kyongbo Pharmaceutical Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$520.5k$106.8k$413.6k79.5%
Net Profit Margin1.2%0.2%--

How much money comes from the company's main activities?

3. Financial Health of Kyongbo Pharmaceutical Co Ltd (5 min.)




What can you expect buying and holding a share of Kyongbo Pharmaceutical Co Ltd? (5 min.)

Welcome investor! Kyongbo Pharmaceutical Co Ltd's management wants to use your money to grow the business. In return you get a share of Kyongbo Pharmaceutical Co Ltd.

What can you expect buying and holding a share of Kyongbo Pharmaceutical Co Ltd?

First you should know what it really means to hold a share of Kyongbo Pharmaceutical Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Kyongbo Pharmaceutical Co Ltd is ₩7,440. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kyongbo Pharmaceutical Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kyongbo Pharmaceutical Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩6,039.32. Based on the TTM, the Book Value Change Per Share is ₩7.08 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-20.88 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩24.94 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kyongbo Pharmaceutical Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.060.0%0.030.0%0.000.0%0.020.0%0.060.0%
Usd Book Value Change Per Share0.070.0%0.000.0%-0.010.0%-0.010.0%0.110.0%
Usd Dividend Per Share0.000.0%0.020.0%0.030.0%0.040.0%0.060.0%
Usd Total Gains Per Share0.070.0%0.020.0%0.020.0%0.030.0%0.170.0%
Usd Price Per Share5.87-5.08-5.44-6.52-7.65-
Price to Earnings Ratio24.61-42.13-256.09-77.42-50.96-
Price-to-Total Gains Ratio87.29-84.14--276.45--23.92--179.51-
Price to Book Ratio1.39-1.22-1.30-1.50-1.92-
Price-to-Total Gains Ratio87.29-84.14--276.45--23.92--179.51-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.208
Number of shares192
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.04
Usd Book Value Change Per Share0.00-0.01
Usd Total Gains Per Share0.020.03
Gains per Quarter (192 shares)4.306.08
Gains per Year (192 shares)17.2224.33
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1134730-514
22782459-1038
340114189-1662
4541558118-2186
5671975148-26110
6802392177-31134
79427109207-36158
810730126236-42182
912134143266-47206
1013438160295-52230

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%8.04.00.066.7%15.05.00.075.0%32.06.00.084.2%32.06.00.084.2%
Book Value Change Per Share3.01.00.075.0%4.08.00.033.3%9.011.00.045.0%22.014.02.057.9%22.014.02.057.9%
Dividend per Share2.00.02.050.0%9.00.03.075.0%14.00.06.070.0%25.00.013.065.8%25.00.013.065.8%
Total Gains per Share3.01.00.075.0%6.06.00.050.0%13.07.00.065.0%29.08.01.076.3%29.08.01.076.3%

Fundamentals of Kyongbo Pharmaceutical Co Ltd

About Kyongbo Pharmaceutical Co Ltd

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research and development of Clopidogrel cardiovascular drug, Imatinlb anticancer drug, Donepezil anti-psychotic drug, Entecavir for anti-virus and infectious disease, and Esomeprazole. It also exports its products. The company was formerly known as Kyongbo Chemical Co. Ltd. and changed its name to Kyongbo Pharmaceutical Co., Ltd in March 2002. Kyongbo Pharmaceutical Co., Ltd was founded in 1987 and is headquartered in Asan-si, South Korea.

Fundamental data was last updated by Penke on 2024-04-16 05:19:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Kyongbo Pharmaceutical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kyongbo Pharmaceutical Co Ltd earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Kyongbo Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 3.3% means that ₩0.03 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kyongbo Pharmaceutical Co Ltd:

  • The MRQ is 3.3%. The company is making a profit. +1
  • The TTM is 1.2%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ3.3%TTM1.2%+2.1%
TTM1.2%YOY0.2%+1.1%
TTM1.2%5Y0.7%+0.5%
5Y0.7%10Y3.9%-3.2%
1.1.2. Return on Assets

Shows how efficient Kyongbo Pharmaceutical Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kyongbo Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.8% Return on Assets means that Kyongbo Pharmaceutical Co Ltd generated ₩0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kyongbo Pharmaceutical Co Ltd:

  • The MRQ is 0.8%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.3%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.8%TTM0.3%+0.5%
TTM0.3%YOY0.1%+0.2%
TTM0.3%5Y0.2%+0.1%
5Y0.2%10Y0.8%-0.6%
1.1.3. Return on Equity

Shows how efficient Kyongbo Pharmaceutical Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kyongbo Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.4% Return on Equity means Kyongbo Pharmaceutical Co Ltd generated ₩0.01 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kyongbo Pharmaceutical Co Ltd:

  • The MRQ is 1.4%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.5%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.4%TTM0.5%+0.9%
TTM0.5%YOY0.1%+0.4%
TTM0.5%5Y0.4%+0.2%
5Y0.4%10Y1.3%-0.9%

1.2. Operating Efficiency of Kyongbo Pharmaceutical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kyongbo Pharmaceutical Co Ltd is operating .

  • Measures how much profit Kyongbo Pharmaceutical Co Ltd makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kyongbo Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kyongbo Pharmaceutical Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.4%-0.4%
TTM0.4%YOY0.3%+0.1%
TTM0.4%5Y1.1%-0.7%
5Y1.1%10Y6.1%-4.9%
1.2.2. Operating Ratio

Measures how efficient Kyongbo Pharmaceutical Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.65 means that the operating costs are ₩1.65 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Kyongbo Pharmaceutical Co Ltd:

  • The MRQ is 1.651. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.189. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.651TTM1.189+0.462
TTM1.189YOY0.997+0.193
TTM1.1895Y1.032+0.158
5Y1.03210Y0.964+0.067

1.3. Liquidity of Kyongbo Pharmaceutical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kyongbo Pharmaceutical Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.15 means the company has ₩1.15 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Kyongbo Pharmaceutical Co Ltd:

  • The MRQ is 1.149. The company is just able to pay all its short-term debts.
  • The TTM is 1.146. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.149TTM1.146+0.003
TTM1.146YOY1.262-0.116
TTM1.1465Y1.387-0.241
5Y1.38710Y1.389-0.002
1.3.2. Quick Ratio

Measures if Kyongbo Pharmaceutical Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kyongbo Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.48 means the company can pay off ₩0.48 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kyongbo Pharmaceutical Co Ltd:

  • The MRQ is 0.482. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.524. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.482TTM0.524-0.041
TTM0.524YOY0.586-0.062
TTM0.5245Y0.710-0.186
5Y0.71010Y0.670+0.040

1.4. Solvency of Kyongbo Pharmaceutical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kyongbo Pharmaceutical Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kyongbo Pharmaceutical Co Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.46 means that Kyongbo Pharmaceutical Co Ltd assets are financed with 45.8% credit (debt) and the remaining percentage (100% - 45.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kyongbo Pharmaceutical Co Ltd:

  • The MRQ is 0.458. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.443. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.458TTM0.443+0.015
TTM0.443YOY0.389+0.054
TTM0.4435Y0.393+0.049
5Y0.39310Y0.383+0.010
1.4.2. Debt to Equity Ratio

Measures if Kyongbo Pharmaceutical Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kyongbo Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 84.4% means that company has ₩0.84 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kyongbo Pharmaceutical Co Ltd:

  • The MRQ is 0.844. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.796. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.844TTM0.796+0.048
TTM0.796YOY0.638+0.159
TTM0.7965Y0.653+0.143
5Y0.65310Y0.6530.000

2. Market Valuation of Kyongbo Pharmaceutical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Kyongbo Pharmaceutical Co Ltd generates.

  • Above 15 is considered overpriced but always compare Kyongbo Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 24.61 means the investor is paying ₩24.61 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kyongbo Pharmaceutical Co Ltd:

  • The EOD is 21.827. Based on the earnings, the company is fair priced.
  • The MRQ is 24.614. Based on the earnings, the company is fair priced.
  • The TTM is 42.128. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD21.827MRQ24.614-2.787
MRQ24.614TTM42.128-17.514
TTM42.128YOY256.088-213.960
TTM42.1285Y77.423-35.294
5Y77.42310Y50.958+26.464
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kyongbo Pharmaceutical Co Ltd:

  • The EOD is 5.747. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 6.480. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -16.636. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD5.747MRQ6.480-0.734
MRQ6.480TTM-16.636+23.117
TTM-16.636YOY23.055-39.691
TTM-16.6365Y-0.507-16.130
5Y-0.50710Y64.266-64.772
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kyongbo Pharmaceutical Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.39 means the investor is paying ₩1.39 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Kyongbo Pharmaceutical Co Ltd:

  • The EOD is 1.232. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.389. Based on the equity, the company is underpriced. +1
  • The TTM is 1.217. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.232MRQ1.389-0.157
MRQ1.389TTM1.217+0.172
TTM1.217YOY1.296-0.079
TTM1.2175Y1.499-0.282
5Y1.49910Y1.924-0.425
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Kyongbo Pharmaceutical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--96.1187.083+1257%-20.880+122%-9.685+110%158.929-40%
Book Value Per Share--6039.3205951.539+1%5985.949+1%6178.415-2%5563.724+9%
Current Ratio--1.1491.146+0%1.262-9%1.387-17%1.389-17%
Debt To Asset Ratio--0.4580.443+3%0.389+18%0.393+16%0.383+19%
Debt To Equity Ratio--0.8440.796+6%0.638+32%0.653+29%0.653+29%
Dividend Per Share---24.944-100%50.000-100%54.950-100%90.614-100%
Eps--85.21548.341+76%6.385+1235%25.945+228%82.449+3%
Free Cash Flow Per Share--323.670-63.067+119%-31.969+110%-1.427+100%-19.662+106%
Free Cash Flow To Equity Per Share--323.670-41.843+113%36.931+776%19.316+1576%9.247+3400%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.791+26%
Intrinsic Value_10Y_max--10914.749--------
Intrinsic Value_10Y_min--9010.427--------
Intrinsic Value_1Y_max--45.771--------
Intrinsic Value_1Y_min--44.342--------
Intrinsic Value_3Y_max--936.194--------
Intrinsic Value_3Y_min--877.644--------
Intrinsic Value_5Y_max--2789.503--------
Intrinsic Value_5Y_min--2520.404--------
Market Cap177867336000.000-13%200578891000.000173520628187.500+16%185816380250.000+8%222869488585.000-10%261591814301.316-23%
Net Profit Margin--0.0330.012+170%0.002+1753%0.007+353%0.039-15%
Operating Margin---0.004-100%0.003-100%0.011-100%0.061-100%
Operating Ratio--1.6511.189+39%0.997+66%1.032+60%0.964+71%
Pb Ratio1.232-13%1.3891.217+14%1.296+7%1.499-7%1.924-28%
Pe Ratio21.827-13%24.61442.128-42%256.088-90%77.423-68%50.958-52%
Price Per Share7440.000-13%8390.0007250.000+16%7772.500+8%9317.000-10%10933.947-23%
Price To Free Cash Flow Ratio5.747-13%6.480-16.636+357%23.055-72%-0.507+108%64.266-90%
Price To Total Gains Ratio77.404-13%87.28884.144+4%-276.450+417%-23.916+127%-179.510+306%
Quick Ratio--0.4820.524-8%0.586-18%0.710-32%0.670-28%
Return On Assets--0.0080.003+172%0.001+1201%0.002+264%0.008-9%
Return On Equity--0.0140.005+173%0.001+1247%0.004+297%0.013+11%
Total Gains Per Share--96.11832.027+200%29.120+230%45.265+112%249.543-61%
Usd Book Value--101066994.86199709711.521+1%100173836.592+1%103456416.285-2%93170288.777+8%
Usd Book Value Change Per Share--0.0670.005+1257%-0.015+122%-0.007+110%0.111-40%
Usd Book Value Per Share--4.2284.166+1%4.190+1%4.325-2%3.895+9%
Usd Dividend Per Share---0.017-100%0.035-100%0.038-100%0.063-100%
Usd Eps--0.0600.034+76%0.004+1235%0.018+228%0.058+3%
Usd Free Cash Flow--5416555.361-1055742.875+119%-534990.559+110%-23269.961+100%-328579.691+106%
Usd Free Cash Flow Per Share--0.227-0.044+119%-0.022+110%-0.001+100%-0.014+106%
Usd Free Cash Flow To Equity Per Share--0.227-0.029+113%0.026+776%0.014+1576%0.006+3400%
Usd Market Cap124507135.200-13%140405223.700121464439.731+16%130071466.175+8%156008642.010-10%183114270.011-23%
Usd Price Per Share5.208-13%5.8735.075+16%5.441+8%6.522-10%7.654-23%
Usd Profit--1426052.775520520.074+174%106853.266+1235%377282.386+278%1350257.989+6%
Usd Revenue--42887280.28937862559.341+13%34346357.864+25%34659565.975+24%33797047.121+27%
Usd Total Gains Per Share--0.0670.022+200%0.020+230%0.032+112%0.175-61%
 EOD+4 -4MRQTTM+25 -10YOY+25 -105Y+20 -1510Y+19 -17

3.2. Fundamental Score

Let's check the fundamental score of Kyongbo Pharmaceutical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1521.827
Price to Book Ratio (EOD)Between0-11.232
Net Profit Margin (MRQ)Greater than00.033
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.482
Current Ratio (MRQ)Greater than11.149
Debt to Asset Ratio (MRQ)Less than10.458
Debt to Equity Ratio (MRQ)Less than10.844
Return on Equity (MRQ)Greater than0.150.014
Return on Assets (MRQ)Greater than0.050.008
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Kyongbo Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose7,440.000
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Other Current Assets  -21-1000061,18661,186
Long-term Assets Other  3,184,2454,937,6548,121,899-696,3547,425,545-7,425,5450-10
Selling General Administrative  29,733,635-16,526,45413,207,1811,111,47714,318,658-47,86714,270,791-20,283,941-6,013,150



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets266,305,017
Total Liabilities121,923,596
Total Stockholder Equity144,381,421
 As reported
Total Liabilities 121,923,596
Total Stockholder Equity+ 144,381,421
Total Assets = 266,305,017

Assets

Total Assets266,305,017
Total Current Assets135,902,171
Long-term Assets130,402,846
Total Current Assets
Cash And Cash Equivalents 4,477,057
Short-term Investments 870,000
Net Receivables 56,159,775
Inventory 70,664,250
Other Current Assets 61,186
Total Current Assets  (as reported)135,902,171
Total Current Assets  (calculated)132,232,268
+/- 3,669,903
Long-term Assets
Property Plant Equipment 96,073,291
Intangible Assets 3,640,573
Long-term Assets  (as reported)130,402,846
Long-term Assets  (calculated)99,713,864
+/- 30,688,982

Liabilities & Shareholders' Equity

Total Current Liabilities118,261,261
Long-term Liabilities3,662,334
Total Stockholder Equity144,381,421
Total Current Liabilities
Short Long Term Debt 73,184,666
Accounts payable 22,775,302
Other Current Liabilities 1,465,065
Total Current Liabilities  (as reported)118,261,261
Total Current Liabilities  (calculated)97,425,033
+/- 20,836,228
Long-term Liabilities
Long term Debt 45,000
Capital Lease Obligations Min Short Term Debt2,706,631
Long-term Liabilities Other 740,813
Long-term Liabilities  (as reported)3,662,334
Long-term Liabilities  (calculated)3,492,445
+/- 169,890
Total Stockholder Equity
Retained Earnings 96,032,570
Total Stockholder Equity (as reported)144,381,421
Total Stockholder Equity (calculated)96,032,570
+/- 48,348,851
Other
Capital Stock11,953,430
Common Stock Shares Outstanding 23,907
Net Debt 68,752,610
Net Invested Capital 217,611,087
Net Working Capital 17,640,909
Property Plant and Equipment Gross 233,822,359



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-30
> Total Assets 
0
0
168,034,561
0
213,209,712
190,888,900
195,488,457
196,839,912
207,553,534
204,383,096
203,735,980
205,088,352
207,565,543
210,834,380
204,869,399
207,163,971
216,751,460
219,596,580
221,622,993
228,954,802
230,374,089
227,045,067
237,816,742
244,516,939
261,559,105
261,247,915
253,239,177
250,146,367
250,175,228
239,934,746
236,979,153
231,323,130
228,847,929
236,641,394
240,544,943
246,266,506
247,852,449
263,285,490
266,305,017
266,305,017263,285,490247,852,449246,266,506240,544,943236,641,394228,847,929231,323,130236,979,153239,934,746250,175,228250,146,367253,239,177261,247,915261,559,105244,516,939237,816,742227,045,067230,374,089228,954,802221,622,993219,596,580216,751,460207,163,971204,869,399210,834,380207,565,543205,088,352203,735,980204,383,096207,553,534196,839,912195,488,457190,888,900213,209,7120168,034,56100
   > Total Current Assets 
0
0
97,476,890
0
129,305,381
99,853,835
105,108,130
103,853,336
107,412,380
101,044,851
102,226,920
105,488,701
109,731,661
113,677,796
110,638,039
114,877,916
126,535,066
127,886,045
128,936,315
135,851,667
137,240,855
128,575,847
124,176,490
133,431,777
150,867,046
152,149,228
138,192,492
132,931,232
127,272,218
115,224,863
111,166,321
108,501,203
109,565,263
116,911,440
116,325,650
117,957,290
118,692,914
133,826,807
135,902,171
135,902,171133,826,807118,692,914117,957,290116,325,650116,911,440109,565,263108,501,203111,166,321115,224,863127,272,218132,931,232138,192,492152,149,228150,867,046133,431,777124,176,490128,575,847137,240,855135,851,667128,936,315127,886,045126,535,066114,877,916110,638,039113,677,796109,731,661105,488,701102,226,920101,044,851107,412,380103,853,336105,108,13099,853,835129,305,381097,476,89000
       Cash And Cash Equivalents 
0
0
6,952,959
0
41,727,162
4,740,323
4,404,474
7,561,897
4,892,254
6,547,208
4,580,309
5,786,529
5,033,451
9,335,300
6,403,652
802,436
4,667,509
5,035,544
4,985,877
5,293,703
7,490,474
3,033,404
6,768,829
5,888,828
2,500,898
12,642,407
11,439,285
12,897,336
7,833,076
7,549,840
4,290,311
7,193,291
4,333,998
7,489,752
6,348,480
8,021,604
4,258,300
1,797,944
4,477,057
4,477,0571,797,9444,258,3008,021,6046,348,4807,489,7524,333,9987,193,2914,290,3117,549,8407,833,07612,897,33611,439,28512,642,4072,500,8985,888,8286,768,8293,033,4047,490,4745,293,7034,985,8775,035,5444,667,509802,4366,403,6529,335,3005,033,4515,786,5294,580,3096,547,2084,892,2547,561,8974,404,4744,740,32341,727,16206,952,95900
       Short-term Investments 
0
0
0
0
-712,038
0
0
0
-1,693,798
0
0
-1,676,748
0
-1,491,748
-1,321,328
0
0
-1,426,448
-1,576,448
0
-1,830,528
-935,449
-1,053,049
1,543,262
9,543,262
9,543,262
9,543,262
5,000,000
10,124
-1,327,241
-1,161,090
0
870,000
870,000
870,000
3,477,600
3,495,601
2,214,800
870,000
870,0002,214,8003,495,6013,477,600870,000870,000870,0000-1,161,090-1,327,24110,1245,000,0009,543,2629,543,2629,543,2621,543,262-1,053,049-935,449-1,830,5280-1,576,448-1,426,44800-1,321,328-1,491,7480-1,676,74800-1,693,798000-712,0380000
       Net Receivables 
0
0
0
0
45,872,182
51,240,910
51,181,379
0
51,959,784
0
50,077,660
0
55,397,930
53,103,747
56,269,964
62,896,404
65,498,614
68,412,814
70,456,124
63,783,308
64,282,229
59,153,465
55,095,162
59,323,215
67,410,235
66,009,605
55,036,584
56,533,752
62,237,323
53,037,063
49,206,132
41,885,647
41,290,917
44,581,613
51,664,402
44,566,645
44,549,873
55,642,456
56,159,775
56,159,77555,642,45644,549,87344,566,64551,664,40244,581,61341,290,91741,885,64749,206,13253,037,06362,237,32356,533,75255,036,58466,009,60567,410,23559,323,21555,095,16259,153,46564,282,22963,783,30870,456,12468,412,81465,498,61462,896,40456,269,96453,103,74755,397,930050,077,660051,959,784051,181,37951,240,91045,872,1820000
       Other Current Assets 
0
0
47,416,468
0
-1
1
0
45,155,596
1
48,429,869
0
47,559,697
-1
54,016,929
1
63,995,821
68,427,257
1
0
68,226,601
1,309,288
2,823,477
0
1
-1
0
0
0
0
-1
0
0
0
-1
-2
-1
0
0
61,186
61,18600-1-2-1000-10000-1102,823,4771,309,28868,226,6010168,427,25763,995,821154,016,929-147,559,697048,429,869145,155,59601-1047,416,46800
   > Long-term Assets 
0
0
70,557,671
0
83,904,331
91,035,065
90,380,328
92,986,576
100,141,154
103,338,245
101,509,059
99,599,650
97,833,882
97,156,584
94,231,360
92,286,054
90,216,394
91,710,535
92,686,677
93,103,135
93,133,233
98,469,220
113,640,251
111,085,163
110,692,059
109,098,687
115,046,684
117,215,135
122,903,010
124,709,882
125,812,832
122,821,927
119,282,666
119,729,953
124,219,293
128,309,216
129,159,536
129,458,683
130,402,846
130,402,846129,458,683129,159,536128,309,216124,219,293119,729,953119,282,666122,821,927125,812,832124,709,882122,903,010117,215,135115,046,684109,098,687110,692,059111,085,163113,640,25198,469,22093,133,23393,103,13592,686,67791,710,53590,216,39492,286,05494,231,36097,156,58497,833,88299,599,650101,509,059103,338,245100,141,15492,986,57690,380,32891,035,06583,904,331070,557,67100
       Property Plant Equipment 
0
0
55,285,405
0
68,316,107
75,349,247
74,892,236
76,197,211
82,658,960
86,070,769
83,949,070
81,872,723
80,470,075
80,024,557
78,497,115
76,889,728
74,938,854
76,200,784
76,497,132
76,139,219
75,616,376
76,628,978
90,390,833
87,610,929
86,133,241
87,177,381
90,100,147
91,498,007
92,956,741
93,908,351
95,677,138
94,179,513
92,123,007
92,980,860
93,918,545
95,742,619
95,745,979
95,466,747
96,073,291
96,073,29195,466,74795,745,97995,742,61993,918,54592,980,86092,123,00794,179,51395,677,13893,908,35192,956,74191,498,00790,100,14787,177,38186,133,24187,610,92990,390,83376,628,97875,616,37676,139,21976,497,13276,200,78474,938,85476,889,72878,497,11580,024,55780,470,07581,872,72383,949,07086,070,76982,658,96076,197,21174,892,23675,349,24768,316,107055,285,40500
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
3,069,528
2,924,244
1,221,997
1,172,664
1,162,185
1,183,824
1,410,376
2,548,923
1,744,492
6,036,114
6,324,914
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000006,324,9146,036,1141,744,4922,548,9231,410,3761,183,8241,162,1851,172,6641,221,9972,924,2443,069,528000000000000
       Intangible Assets 
0
0
2,068,775
0
1,886,634
1,783,311
1,644,205
2,676,616
2,602,776
2,393,280
3,350,632
3,164,081
2,967,867
2,763,671
2,584,179
2,634,667
2,502,437
2,404,812
2,499,412
2,347,814
3,432,754
3,556,390
3,482,441
3,292,134
3,226,158
3,205,006
3,090,536
2,940,752
2,907,816
2,870,137
3,354,766
3,290,064
3,183,619
3,157,407
3,221,057
3,293,741
3,274,823
3,136,622
3,640,573
3,640,5733,136,6223,274,8233,293,7413,221,0573,157,4073,183,6193,290,0643,354,7662,870,1372,907,8162,940,7523,090,5363,205,0063,226,1583,292,1343,482,4413,556,3903,432,7542,347,8142,499,4122,404,8122,502,4372,634,6672,584,1792,763,6712,967,8673,164,0813,350,6322,393,2802,602,7762,676,6161,644,2051,783,3111,886,63402,068,77500
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
1
11,326,412
11,444,112
11,928,068
1
11,612,918
11,921,115
12,279,758
12,067,179
0
12,247,737
13,442,063
0
0
8,962,681
10,028,452
9,736,035
9,990,184
11,287,949
12,397,196
12,903,070
13,419,768
0
0
0
17,438,841
0
0
0017,438,84100013,419,76812,903,07012,397,19611,287,9499,990,1849,736,03510,028,4528,962,6810013,442,06312,247,737012,067,17912,279,75811,921,11511,612,918111,928,06811,444,11211,326,412100000000000
> Total Liabilities 
0
0
99,704,705
0
104,373,490
77,924,498
72,671,307
76,441,514
84,055,352
79,744,745
74,333,640
75,615,345
73,402,455
72,363,788
63,359,803
67,081,129
72,893,817
73,462,202
72,610,828
82,697,496
80,530,976
75,886,225
88,653,237
95,999,151
108,835,881
105,598,905
97,182,383
94,845,028
96,170,510
90,605,209
91,278,423
87,014,568
86,341,712
94,738,304
96,840,887
105,013,264
105,800,859
121,201,963
121,923,596
121,923,596121,201,963105,800,859105,013,26496,840,88794,738,30486,341,71287,014,56891,278,42390,605,20996,170,51094,845,02897,182,383105,598,905108,835,88195,999,15188,653,23775,886,22580,530,97682,697,49672,610,82873,462,20272,893,81767,081,12963,359,80372,363,78873,402,45575,615,34574,333,64079,744,74584,055,35276,441,51472,671,30777,924,498104,373,490099,704,70500
   > Total Current Liabilities 
0
0
85,615,616
0
89,517,195
66,972,967
64,542,191
67,416,290
78,748,408
73,856,698
72,716,830
74,835,432
72,312,299
70,526,334
60,379,395
64,737,048
69,837,119
69,896,293
69,317,865
79,547,652
76,542,796
71,216,206
83,814,952
91,384,676
102,942,704
100,005,529
93,763,557
92,169,897
92,500,350
87,076,005
88,814,156
85,521,119
84,250,098
92,538,170
95,569,006
102,405,456
103,248,097
118,065,892
118,261,261
118,261,261118,065,892103,248,097102,405,45695,569,00692,538,17084,250,09885,521,11988,814,15687,076,00592,500,35092,169,89793,763,557100,005,529102,942,70491,384,67683,814,95271,216,20676,542,79679,547,65269,317,86569,896,29369,837,11964,737,04860,379,39570,526,33472,312,29974,835,43272,716,83073,856,69878,748,40867,416,29064,542,19166,972,96789,517,195085,615,61600
       Short-term Debt 
0
0
37,277,959
0
39,038,588
17,388,204
34,090,028
30,786,078
42,814,455
42,726,019
41,082,535
43,669,101
47,719,549
36,911,343
28,375,875
22,185,655
36,735,347
36,891,764
42,120,856
42,855,460
45,700,451
44,494,946
54,512,100
55,158,622
70,897,904
67,274,483
62,073,522
62,549,885
67,745,442
63,406,520
56,110,792
57,893,135
53,985,666
59,830,459
64,270,589
68,580,199
68,472,002
0
0
0068,472,00268,580,19964,270,58959,830,45953,985,66657,893,13556,110,79263,406,52067,745,44262,549,88562,073,52267,274,48370,897,90455,158,62254,512,10044,494,94645,700,45142,855,46042,120,85636,891,76436,735,34722,185,65528,375,87536,911,34347,719,54943,669,10141,082,53542,726,01942,814,45530,786,07834,090,02817,388,20439,038,588037,277,95900
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
47,719,549
37,040,343
28,826,975
22,636,755
37,186,447
0
0
42,675,499
45,512,280
44,176,328
53,693,170
54,350,064
70,095,357
66,489,500
61,308,414
61,790,000
66,963,140
62,621,704
55,323,768
57,147,815
53,390,000
59,390,000
63,990,000
67,890,000
67,690,000
79,590,000
73,184,666
73,184,66679,590,00067,690,00067,890,00063,990,00059,390,00053,390,00057,147,81555,323,76862,621,70466,963,14061,790,00061,308,41466,489,50070,095,35754,350,06453,693,17044,176,32845,512,28042,675,4990037,186,44722,636,75528,826,97537,040,34347,719,549000000000000
       Accounts payable 
0
0
18,288,508
0
14,986,366
16,588,092
16,602,104
14,386,952
14,653,926
13,297,571
15,716,878
16,148,844
12,996,821
16,761,848
15,450,647
20,732,898
21,174,041
18,140,614
15,020,329
18,561,147
17,484,464
12,616,926
15,296,391
20,549,274
17,687,017
16,656,768
14,293,367
13,365,665
11,237,779
9,211,155
16,404,016
12,884,320
17,793,913
18,656,796
14,742,474
17,273,558
16,294,009
20,469,251
22,775,302
22,775,30220,469,25116,294,00917,273,55814,742,47418,656,79617,793,91312,884,32016,404,0169,211,15511,237,77913,365,66514,293,36716,656,76817,687,01720,549,27415,296,39112,616,92617,484,46418,561,14715,020,32918,140,61421,174,04120,732,89815,450,64716,761,84812,996,82116,148,84415,716,87813,297,57114,653,92614,386,95216,602,10416,588,09214,986,366018,288,50800
       Other Current Liabilities 
0
0
0
0
24,289,402
-1
0
20,530,612
-1
1
0
1
-1
-1
-1
-2
1
1
0
17,001,420
539,518
502,055
642,935
975,079
1,005,753
1,049,672
1,267,419
1,320,638
1,341,846
1,386,279
1,330,386
14,743,664
12,470,519
14,050,915
16,555,943
16,551,700
1,259,292
1,321,268
1,465,065
1,465,0651,321,2681,259,29216,551,70016,555,94314,050,91512,470,51914,743,6641,330,3861,386,2791,341,8461,320,6381,267,4191,049,6721,005,753975,079642,935502,055539,51817,001,420011-2-1-1-1101-120,530,6120-124,289,4020000
   > Long-term Liabilities 
0
0
14,089,089
0
14,856,295
10,951,531
8,129,116
9,025,224
5,306,945
5,888,047
1,616,810
779,913
1,090,156
1,837,454
2,980,407
2,344,081
3,056,698
3,565,909
3,292,963
3,149,844
3,988,180
4,670,019
4,838,286
4,614,475
5,893,177
5,593,376
3,418,826
2,675,131
3,670,160
3,529,204
2,464,267
1,493,449
2,091,614
2,200,134
1,271,881
2,607,808
2,552,762
3,136,071
3,662,334
3,662,3343,136,0712,552,7622,607,8081,271,8812,200,1342,091,6141,493,4492,464,2673,529,2043,670,1602,675,1313,418,8265,593,3765,893,1774,614,4754,838,2864,670,0193,988,1803,149,8443,292,9633,565,9093,056,6982,344,0812,980,4071,837,4541,090,156779,9131,616,8105,888,0475,306,9459,025,2248,129,11610,951,53114,856,295014,089,08900
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
1,090,156
1,708,454
2,529,307
1,892,981
2,605,598
3,114,809
2,841,863
2,698,744
3,271,453
3,705,704
2,928,057
2,882,342
4,331,969
4,213,344
2,226,940
1,650,859
2,804,093
2,852,031
1,988,520
1,138,285
1,772,266
1,919,964
1,030,299
0
1,090,797
0
0
001,090,79701,030,2991,919,9641,772,2661,138,2851,988,5202,852,0312,804,0931,650,8592,226,9404,213,3444,331,9692,882,3422,928,0573,705,7043,271,4532,698,7442,841,8633,114,8092,605,5981,892,9812,529,3071,708,4541,090,156000000000000
> Total Stockholder Equity
0
0
68,329,856
0
108,836,221
112,964,402
122,817,151
120,398,398
123,498,182
124,638,351
129,402,340
129,473,007
134,163,088
138,470,591
141,509,596
140,082,842
143,857,643
146,134,377
149,012,166
146,257,305
149,843,113
151,158,842
149,163,504
148,517,788
152,723,224
155,649,009
156,056,793
155,301,339
154,004,718
149,329,537
145,700,731
144,308,562
142,506,217
141,903,090
143,704,056
141,253,242
142,051,590
142,083,527
144,381,421
144,381,421142,083,527142,051,590141,253,242143,704,056141,903,090142,506,217144,308,562145,700,731149,329,537154,004,718155,301,339156,056,793155,649,009152,723,224148,517,788149,163,504151,158,842149,843,113146,257,305149,012,166146,134,377143,857,643140,082,842141,509,596138,470,591134,163,088129,473,007129,402,340124,638,351123,498,182120,398,398122,817,151112,964,402108,836,221068,329,85600
   Common Stock
0
0
10,758,085
0
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
11,953,430
0
0
0011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,43011,953,430010,758,08500
   Retained Earnings Total Equity000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
6,529,004
0
41,126,082
40,590,118
40,726,066
40,721,626
40,669,211
40,479,425
40,358,642
40,559,205
40,451,588
40,338,266
39,434,136
39,981,528
39,979,842
40,003,184
43,456,480
39,921,265
39,916,418
39,899,324
43,884,568
39,898,047
39,903,942
39,899,218
39,895,921
39,882,608
40,079,924
39,714,393
39,159,828
38,434,391
37,406,725
36,693,537
37,055,187
36,672,669
36,594,804
0
0
0036,594,80436,672,66937,055,18736,693,53737,406,72538,434,39139,159,82839,714,39340,079,92439,882,60839,895,92139,899,21839,903,94239,898,04743,884,56839,899,32439,916,41839,921,26543,456,48040,003,18439,979,84239,981,52839,434,13640,338,26640,451,58840,559,20540,358,64240,479,42540,669,21140,721,62640,726,06640,590,11841,126,08206,529,00400



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue216,357,482
Cost of Revenue-153,282,206
Gross Profit63,075,27663,075,276
 
Operating Income (+$)
Gross Profit63,075,276
Operating Expense-210,812,710
Operating Income5,544,772-147,737,435
 
Operating Expense (+$)
Research Development3,653,609
Selling General Administrative35,783,480
Selling And Marketing Expenses0
Operating Expense210,812,71039,437,089
 
Net Interest Income (+$)
Interest Income143,420
Interest Expense-3,400,954
Other Finance Cost-1
Net Interest Income-3,257,535
 
Pretax Income (+$)
Operating Income5,544,772
Net Interest Income-3,257,535
Other Non-Operating Income Expenses0
Income Before Tax (EBT)2,171,9245,544,772
EBIT - interestExpense = -3,400,954
2,974,400
6,375,354
Interest Expense3,400,954
Earnings Before Interest and Taxes (EBIT)05,572,878
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax2,171,924
Tax Provision--802,476
Net Income From Continuing Ops2,974,4002,974,400
Net Income2,974,400
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net03,257,535
 

Technical Analysis of Kyongbo Pharmaceutical Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kyongbo Pharmaceutical Co Ltd. The general trend of Kyongbo Pharmaceutical Co Ltd is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kyongbo Pharmaceutical Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kyongbo Pharmaceutical Co Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 7,440 < 7,440 < 7,440.

The bearish price targets are: 7,440 > 7,440 > 7,440.

Tweet this
Kyongbo Pharmaceutical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kyongbo Pharmaceutical Co Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kyongbo Pharmaceutical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kyongbo Pharmaceutical Co Ltd.

Kyongbo Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartKyongbo Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kyongbo Pharmaceutical Co Ltd. The current adx is .

Kyongbo Pharmaceutical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kyongbo Pharmaceutical Co Ltd.

Kyongbo Pharmaceutical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kyongbo Pharmaceutical Co Ltd.

Kyongbo Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) ChartKyongbo Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kyongbo Pharmaceutical Co Ltd.

Kyongbo Pharmaceutical Co Ltd Daily Stochastic Oscillator ChartKyongbo Pharmaceutical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kyongbo Pharmaceutical Co Ltd.

Kyongbo Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) ChartKyongbo Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kyongbo Pharmaceutical Co Ltd.

Kyongbo Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartKyongbo Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kyongbo Pharmaceutical Co Ltd.

Kyongbo Pharmaceutical Co Ltd Daily Williams %R ChartKyongbo Pharmaceutical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kyongbo Pharmaceutical Co Ltd.

Kyongbo Pharmaceutical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kyongbo Pharmaceutical Co Ltd.

Kyongbo Pharmaceutical Co Ltd Daily Average True Range (ATR) ChartKyongbo Pharmaceutical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kyongbo Pharmaceutical Co Ltd.

Kyongbo Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) ChartKyongbo Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kyongbo Pharmaceutical Co Ltd.

Kyongbo Pharmaceutical Co Ltd Daily Money Flow Index (MFI) ChartKyongbo Pharmaceutical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kyongbo Pharmaceutical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Kyongbo Pharmaceutical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kyongbo Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose7,440.000
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kyongbo Pharmaceutical Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Kyongbo Pharmaceutical Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kyongbo Pharmaceutical Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kyongbo Pharmaceutical Co Ltd

I send you an email if I find something interesting about Kyongbo Pharmaceutical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Kyongbo Pharmaceutical Co Ltd.

Receive notifications about Kyongbo Pharmaceutical Co Ltd in your mailbox!